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A B S T R A C T
Background: Patient outcome expectancy - the belief that treatment will lead to an improvement in symptoms –
is linked to favourable therapeutic outcomes in major depressive disorder (MDD). The present study extends this
literature by investigating the temporal dynamics of expectancy, and by exploring whether expectancy during
treatment is linked to differential outcomes across treatment modalities, for both optimistic versus pessimistic
expectancy.
Methods: A total of 104 patients with MDD were randomized to receive either cognitive behavioral therapy
(CBT) or pharmacotherapy for 16 weeks. Outcome expectancy was measured throughout treatment using the
Depression Change Expectancy Scale (DCES). Depression severity was measured using both the Hamilton
Depression Rating Scale and Beck Depression Inventory-II.
Results: Latent growth curve models supported improvement in expectancy across both treatments. Cross-lagged
panel models revealed that both higher optimistic and lower pessimistic expectancy at mid-treatment predicted
greater treatment response in pharmacotherapy. For CBT, the associative patterns between expectancy and
depression differed as a function of expectancy type; higher optimistic expectancy at pre-treatment and lower
pessimistic expectancy at mid-treatment predicted greater treatment response.
Limitations: The sample size limited statistical power and the complexity of models that could be explored.
Conclusions: Results suggest that outcome expectancy improved during treatment for depression. Whether
outcome expectancy represents a specific mechanism for the reduction of depression warrants further in-
vestigation.
1. Introduction
Depression remains the most common mental disorder, with nearly
298 million cases of major depressive disorder (MDD) reported
worldwide in 2010 (Ferrari et al., 2013). Although empirically sup-
ported treatments for MDD exist, including pharmacological and psy-
chological interventions (Lam et al., 2009; Parikh et al., 2016), it is well
recognized that a sizable proportion of patients do not respond to these
treatments (Hofmann et al., 2012; Trivedi et al., 2006). Such findings
highlight the need for a greater understanding of factors that predict
response to treatment in MDD and the mechanisms by which treatment
results in therapeutic change.
Patient expectancies of treatment outcome – that is, prognostic
beliefs of whether treatment will lead to a change in health status - have
been theoretically and empirically linked to both process and outcome
in psychotherapy (Constantino et al., 2011; Glass et al., 2001;
Greenberg et al., 2006) and pharmacotherapy (Rutherford et al., 2010).
Indeed, theoretical models of psychotherapy including Frank's (1961)
theory of remoralization and the Snyder et al. (2000) theory of hope
posit a central role of patient expectancies in symptom improvement
(Constantino et al., 2012; Swift and Derthick, 2013; Westra et al.,
2007). Similarly, expectancy theory posits that conscious expectancies
of improvement mediate the placebo response seen in pharmacological
treatments (Rutherford and Roose, 2013; Stewart-Williams and Podd,
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2004). As overall treatment efficacy has been conceptualized as the sum
of the placebo effect and the effects specific to the active pharma-
cotherapy, more optimistic expectancy may contribute to stronger
treatment response with active medication (Wampold et al., 2005). This
link between outcome expectancy and treatment response has been
demonstrated consistently in individuals with a diagnosis of depression
(Schulte, 2008; Webb et al., 2013).
The majority of the empirical support for the influence of patient
outcome expectancies has been circumscribed to psychotherapy. In a
comprehensive meta-analysis of 46 independent studies, outcome ex-
pectancy at the beginning of psychotherapy was found to have a small,
significant positive association with therapeutic outcomes, such as post-
treatment symptom severity (Cohen's d=0.24; Constantino et al.,
2011). More recent research supports the dynamic nature of this con-
struct within psychotherapy treatment in anxious (Brown et al., 2014;
Newman and Fisher, 2010) and obsessive-compulsive samples
(Vorstenbosch and Laposa, 2015). Change in this construct has also
been demonstrated for treatment of mood disorders. In individuals with
recurrent major depression with a seasonal pattern, outcome ex-
pectancy increased steeply over a 6-week course of group CBT for
seasonal affective disorder (SAD) (Meyerhoff and Rohan, 2016). Fi-
nally, increased outcome expectancy was recently demonstrated in
patients with depression who received a 14-week course of individual
CBT (Vîslă et al., 2018).
This growing literature of dynamic changes in patient expectancy
highlights the importance of evaluating outcome expectancy not only at
pre-treatment, but also during treatment course. The demonstration of
an association between expectancy during treatment and subsequent
symptom improvement may substantiate the mechanistic role of ex-
pectancy. Indeed, change in expectancy during psychotherapy has
predicted symptom severity and functioning level at post-treatment in
several studies (Brown et al., 2014; Newman and Fisher, 2010;
Vorstenbosch and Laposa, 2015), whereas point estimates of outcome
expectancy during treatment were linked to clinical outcomes in others
(Meyerhoff and Rohan, 2016; Visla et al., 2016).
Nevertheless, important questions remain in the literature. First, the
causal significance of this construct across different treatment mod-
alities is presently unclear (Meyerhoff and Rohan, 2016). Comparing
the impact of outcome expectancy across different classes of treatment
can help to clarify whether expectancy of change is a putative common
mechanism for improvement, or whether it is a possible mechanism
specific to treatment change. To this end, exploring the role of outcome
expectancy across cognitive behavioral therapy (CBT) and pharma-
cotherapy, two treatments for depression for which there are compar-
able outcomes and among the strongest evidence base (Cuijpers et al.,
2013), is warranted. Like CBT, there is considerable evidence for the
predictive power of pre-treatment expectancy on therapeutic response
in pharmacotherapy (Meyer et al., 2002; Rutherford et al., 2017, 2010;
Sotsky et al., 1991), although expectancy during pharmacotherapy
treatment has received limited investigation.
Second, the measurement of patient outcome expectancy is con-
sistently recognized as a limitation in the literature to date. As reviewed
by Rutherford et al. (2010), the majority of self-report scales developed
for the assessment of outcome expectancy were purpose-built for a
specific investigation, with limited psychometric validation beyond
those investigations. A further important consideration is that ex-
pectancies can be directed to the likelihood of positive outcomes (i.e.,
optimistic expectancy) as well as negative outcomes (i.e., pessimistic
expectancy; Schulte, 2008), although existing instruments largely assess
only the former. The existence of optimistic and pessimistic ex-
pectancies is highly relevant to MDD in particular; both optimistic and
pessimistic cognitions are seen in this disorder in the form of certainty
in the absence of positive future events (i.e., low optimistic expectancy)
and the presence of negative future events (i.e., high pessimistic ex-
pectancy; Miranda et al., 2008), each proposed to stem from distinct
underlying affective-motivational systems (MacLeod, 1996). In the
context of depression, there is thus a particular need to ascertain both
optimistic and pessimistic expectations of outcomes (Dozois and
Westra, 2005; Eddington et al., 2014; Schulte, 2008).
The current study adds to the growing expectancy literature by first
investigating the temporal dynamics of outcome expectancy during the
course of different treatments for MDD. Specifically, growth is com-
pared across CBT and pharmacotherapy as these treatments represent
empirically supported interventions for MDD with theoretically distinct
mechanisms of action. Second, we investigate whether outcome ex-
pectancy both before and during treatment is predictive of depression
outcome in each treatment. Finally, this study improves upon the cur-
rent literature by measuring outcome expectancy using a more refined
scale (the Depression Change Expectancy Scale (DCES) (Eddington
et al., 2014)) designed to evaluate both pessimistic and optimistic ex-
pectancies specific to depression.
Theoretically, CBT improves depression by targeting cognitions via
both cognitive and behavioral strategies. As reviewed by Lorenzo-
Luaces et al. (2015), there is some evidence that depressive cognitions
undergo the greatest improvements as a result of procedures specifi-
cally aimed at cognitive change such as those used in CBT. Although
cognitive change can also occur in pharmacotherapy (see Garratt et al.,
2007, for review), such change likely stems from other mechanisms (see
Lorenzo-Luaces et al., 2015); the mechanisms of action of anti-
depressants have largely implicated neurobiological targets (Rot et al.,
2009). As such, cognitive changes in pharmacotherapy may represent
“downstream effects”, or may be a reflection of symptom change itself
(DeRubeis et al., 1990). Based on the conceptualization of outcome
expectancy as a cognitive variable, we hypothesize that this variable
will undergo greater change over treatment in the CBT arm relative to
pharmacotherapy. We also hypothesize that the association between
outcome expectancy during treatment and symptom improvement will
be stronger in the CBT arm relative to pharmacotherapy treatment. This
hypothesis is first supported by the centrality of positive expectations to
theories of depression improvement in psychotherapy (Frank, 1961).
Moreover, there is some empirical support that cognitive change is
causally linked to symptom change within the context of therapies
utilizing cognitive-specific procedures (i.e., CBT) and less so in thera-
pies using non-cognitive strategies (DeRubeis et al., 1990; Evans et al.,
2013; Lorenzo-Luaces et al., 2015). Due to limited empirical evidence,
no specific hypotheses were made with respect to the differing role of
optimistic versus pessimistic expectancy.
2. Methods
2.1. Participants
Participants were 104 outpatients diagnosed with MDD who parti-
cipated in a randomized trial of CBT versus pharmacotherapy (Quilty
et al., 2014). Participants met the following inclusion criteria: (i)
having a primary diagnosis of MDD as determined using the Structured
Clinical Interview for DSM-IV Patient Version (SCID-I/P; (First et al.,
1995)); (ii) being between 18 and 65 years of age; (iii) fluency in
English; and (iv) capacity to provide consent. Moreover, participants:
(i) did not have a diagnosis of bipolar disorder, psychotic disorder,
substance dependence or organic brain syndrome; (ii) were not re-
ceiving current treatment with antidepressant medications, and (iii) did
not receive electroconvulsive therapy in the 6-month period prior to
enrollment.
The randomized trial of CBT versus pharmacotherapy (Quilty et al.,
2014) was undertaken to explore the cognitive mediation hypothesis of
treatment for depression, specifically the mediational role of cognitive
structure and processing. Quilty et al. reported that both indices of
cognition improved similarly across CBT and pharmacotherapy but did
not evaluate measures of cognitive content, including outcome ex-
pectancy.
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2.2. Procedures
Participants were recruited using a range of advertisement ap-
proaches. The 104 participants provided written consent to participate
and were randomized to receive either CBT (n=54), or antidepressant
medication (n=50). Stratified randomization was used to match par-
ticipants on gender and depression recurrence across both treatments.
There were 5 dropouts in the CBT group and 7 dropouts in the medi-
cation group, resulting in 49 CBT treatment completers and 43 medi-
cation treatment completers (final N=92). Treatment completers had
completed at least 8 sessions of CBT or weeks of medication.
Four psychiatrists provided treatment in the antidepressant arm,
guided by the Canadian Network for Mood and Anxiety Treatment
(CANMAT) guidelines (Lam et al., 2009). Specifically, the pharma-
cotherapy protocol included eight bi-weekly psychiatric visits ap-
proximately 30 min in duration, and medication switches as per
CANMAT guidelines. Participants in this arm received 13.5 weeks of
medication on average (range: 0–16 weeks). Medications included bu-
propion (n=12), sertraline (n=10), venlafaxine (n=6), citalopram
(n=6), escitalopram (n=5), fluoxetine (n=5), mirtazapine (n=4),
and duloxetine (n=2); six participants were on more than one anti-
depressant. Moreover, they attended 6.5 psychiatric visits on average
(range: 0–9 visits).
Nine therapists provided CBT, guided by the protocol outlined by
Beck and colleagues (Beck et al., 1979). The CBT protocol involved
sixteen weekly visits lasting approximately one hour in duration. Par-
ticipants in the CBT group completed 14.3 sessions on average (range: 1
– 16 visits).
Intraclass correlation coefficients (ICCs) were computed to estimate
the proportion of variance in the variables of interest (outcome ex-
pectancy and depression) explained by assignment to specific thera-
pists/psychiatrists. The ICC values were modest (0.002 to 0.08), not
supporting the need for multi-level models incorporating the effect of
therapists.
2.3. Measures
During treatment, assessments were conducted at four time points:
at pre-treatment (week 0), week 4, week 8 and post-treatment (week
16; Quilty et al., 2014). Outcome expectancy was measured using the
DCES (Eddington et al., 2014). The DCES is a recently developed self-
report questionnaire developed for the measurement of outcome/
change expectancy in depression, modified from an expectancy scale
developed for anxiety disorders (Dozois and Westra, 2005). The DCES
assesses both broad as well as treatment-focused expectations for
change in depression symptoms, using a Likert-type scale ranging from
1 (strongly disagree) to 5 (strongly agree). The DCES comprises the
DCES-P and the DCES-O subscales, which include 11 pessimistically
worded items and 9 optimistically worded items, respectively. The
DCES-P items were reverse scored. In a psychometric evaluation using a
clinical sample, the DCES demonstrated good internal consistency
(coefficient α = 0.75 and 0.82) and expected convergent, divergent,
and predictive validity with respect to short-term improvement in de-
pression symptoms (Eddington et al., 2014).
Depression was measured using the self-reported Beck Depression
Inventory-II (BDI-II; Beck et al., 1996) and the semi-structured, clin-
ician rated Hamilton Depression Rating Scale (HAMD; Hamilton, 1960).
The reliability of these measures within this sample is reported else-
where (Quilty et al., 2014).
2.4. Data analyses
Descriptive statistics were tested using IBM SPSS Statistics Version
24.0, and analyses were conducted using Mplus Version 8.0. Model
parameters were estimated using robust maximum likelihood estima-
tion, which is robust to non-normality (Muthén and Muthén, 2017).
Model fit was ascertained using the following fit indices: chi-square
goodness of fit, standardized root mean square residual (SRMR), root
mean-square error of approximation (RMSEA), and Bentler's Com-
parative Fit Index (CFI). Based on the recommendations of Hu and
Bentler (1999), good model fit was defined as an RMSEA value of
<0.05, SRMR value of <0.08 and a CFI value of >0.95. RMSEA values
of <0.08 were considered indications of adequate model fit and
RMSEA values of >0.10 were considered poor fit (Hu and Bentler,
1999; Kline, 2011). For all models, modification indices were examined
upon indication of possible misspecification. Only theoretically tenable
modifications were considered (Kline, 2011).
Change in outcome expectancy was investigated using latent growth
curve modeling (LGCM) – a growth model approach to estimate be-
tween-participant differences in the latent trajectory of a variable
(Curran et al., 2010). Two latent factors representing the intercept and
slope were estimated, along with the covariance between the two fac-
tors. The mean of the intercept and slope represent fixed effects, in-
dicating the average baseline value and average change over time, re-
spectively. Variability in these factors between participants – i.e.
random effects - are represented with the factor variances (Newsom,
2015). As demonstrated by Preacher et al. (2008), model fitting began
with a random intercept model. A fixed slope parameter was then in-
troduced, and then subsequently freed, allowing growth parameters to
covary; model fit indices were explored at each step of model building
(Preacher et al., 2008). Visual inspection of the pattern of change for
the optimistic and pessimistic subscales of the DCES in the two treat-
ment groups suggested non-linear growth only in the medication group.
As such, both linear (slope loadings= 0, 1, 2, 4) and freely estimated
(slope loadings= 0, *, *, 4) unconditional models were compared for
each subscale in the two treatment groups separately.1
The relation between outcome expectancy and depression
throughout treatment was investigated using cross-lagged panel
models. Cross-lagged models allow for approximation of the causal
relation between variables longitudinally, by accounting for both the
stability within each variable and contemporaneous associations be-
tween variables. Thus, the potential covariation and confounding of
expectancies and response (e.g., patients who are improving to a
greater degree may endorse more positive expectancies) are taken into
account statistically, and not reflected within cross-lagged associations.
As equidistant time intervals are required to ensure unbiased inter-
pretation of results (Kuiper and Ryan, 2018), only week 0, week 8 and
week 16 were included. A multi-group approach was taken to model the
panels separately in the medication and CBT group, allowing for an
exploration of whether the cross-lagged associations differed as a
function of treatment group. To limit the number of tests performed, the
Wald Test of Parameter Constraints (Muthén and Muthén, 2017) was
used to test the equality of the regression parameters in only the cross-
lagged paths from expectancy to depression in the medication versus
CBT treatment groups.
The following cross-lagged panel models were developed to assess
the causal relation between outcome expectancy and depression over
time: pessimistic outcome expectancy modeled with the BDI-II (Model
1) and the HAMD (Model 2), and optimistic outcome expectancy
modeled with the BDI-II (Model 3) and the HAMD (Model 4). Model-
building began with an initial structure applied to all four models,
which included all autoregressive and cross-lagged panel effects with
only a time lag of 1 (i.e., depression at time t on depression at time t + 1
and expectancy at t + 1).
1 Consistent with the observed trends, the freely estimated slope demon-
strated more favorable fit over the linear slope on all indices for the medication
group. For the CBT group, the fit of the two conditional models (linear slope
versus freely estimated slope) was comparable. Importantly, the freely esti-
mated slopes approximated linear change in the CBT group (i.e. estimated slope
loadings= 0, 1.2, 2.4, 4), supporting the observed pattern of change.
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3. Results
3.1. Change in outcome expectancy
Neither outcome expectancy (DCES-P and DCES-O) nor depression
(BDI-II and HAMD) differed between treatment groups at week 0
(ps > 0.05; Table 1). We could not assume measurement invariance
across our treatment groups owing to the differing shapes of the tra-
jectories (and therefore, non-invariant factor loadings; Kim and
Willson, 2014; Newsom, 2015; Preacher et al., 2008). As such, the la-
tent growth curve model (LGCM) analyses were estimated in the CBT
and medication groups separately. Model fits of all final models are
reported in Table 2. Unstandardized parameter estimates from all
LGCMs are reported in Table 3.
3.1.1. Medication
The LGCM for pessimistic outcome expectancy including first a fixed
slope, and then a random slope resulted in a poor fitting and an inad-
missible model solution, respectively. This indicated potential struc-
tural misspecification requiring modification, with the model deemed
uninterpretable. The LGCM for optimistic outcome expectancy in-
cluding a random slope demonstrated the best fit and was used as the
final model (Table 2). The mean slope indicated significant positive
non-linear growth in optimistic outcome expectancy over treatment
(B=1.05, p < .001).
3.1.2. Cognitive behavioral therapy
The LGCM for pessimistic outcome expectancy with a random slope
demonstrated the best fit and was used as the final model (Table 2). The
mean slope indicated significant positive linear growth (B=2.75, p
< .001). For optimistic outcome expectancy, introduction of a random
slope factor resulted in an inadmissible model solution. As such, the
final model included a fixed linear slope, which demonstrated accep-
table model fit (Table 2). The mean slope indicated significant positive
linear growth on average (B=1.47, p < .001).
Taken together, results of the LGCMs supported non-linear growth
in optimistic outcome expectancy within the medication group and
linear growth in optimistic outcome expectancy and (reverse scored)
pessimistic outcome expectancy in CBT. However, for most of the
LGCMs, support for model fit was mixed, with the SRMR values outside
the recommended cutoff (<0.08; see Table 2). As such, the presence of
some model misfit is possible.
3.2. Links between outcome expectancy and depression
Fit indices for the initial lag 1 models are displayed in Table 2.
Based on both extant literature substantiating the relation between pre-
treatment expectancy and post-treatment outcome, and previous work
with similar study aims (Meyerhoff and Rohan, 2016), cross-lagged
paths between week 0 and week 16 for the four models were added.2
3.3. Pessimistic outcome expectancy and depression
All significant paths from Model 1 are shown in Fig. 1. Higher DCES-P
score at mid-treatment predicted lower BDI-II score at the end of treatment
in the CBT group (β=−0.31, p = .02). However, the Wald test was not
significant (χ2(1, n=104)=0.04, p=.85), suggesting that the strength
of the path did not significantly differ between treatment arms.
Using the HAMD to model depression (Model 2), higher DCES-P
score at mid-treatment predicted lower HAMD score at the end of
treatment in the medication group (β=−0.43, p = .004) as well as in
the CBT group (β=−0.32, p = .03). Similar to the results of Model 1,
the Wald test indicated that the estimated coefficients for this path did
not significantly differ across the two arms (χ2(1, n=104)= 0.03, p
= .87). In both Models 1 and 2, none of the paths from depression to
pessimistic outcome expectancy were significant in either of the two
treatment groups (ps > 0.05).
3.4. Optimistic outcome expectancy and depression
All significant paths from Model 3 are shown in Fig. 2. Higher DCES-O
score at pre-treatment predicted lower BDI-II score at mid-treatment in the
medication group (β=−0.30, p = .03), but not the CBT group (β=0.03,
p= .82). However, the difference in this path across the two groups was not
significant (χ2(1, n=104)=3.13, p = .077). Similarly, higher DCES-O
scores at mid-treatment predicted lower BDI-II scores at the end of treat-
ment in the medication group (β=−0.30, p= .04), but not the CBT group
(β=−0.13, p = .41). Testing the difference in this path across treatment
groups revealed no significant differences (χ2(1, n=104)=0.623, p
= .43). Finally, higher DCES-O scores at pre-treatment predicted lower BDI-
II scores at the end of treatment for the CBT group (β=−0.35, p < .001),
but not the medication group (β=0.01, p = .89). The Wald test in this
particular path indicated significant differences between medication and
CBT (χ2(1, n=104)=6.07, p= .01). In the medication group, none of the
depression to outcome expectancy paths emerged as significant (ps>0.05).
However, in the CBT group, the path from BDI-II at week 8 to DCES-O at
week 16 was significantly different from 0 (β=0.29, p = .03).
Table 1
Sample descriptive statistics for depression change expectancy scale measure.
Medication CBT
Variables Means SD Means SD
DCES-O week 0 29.00 5.83 30.52 5.73
DCES-O week 4 31.74 5.64 32.40 4.82
DCES-O week 8 32.85 6.70 34.16 4.60
DCES-O week 16 33.33 7.44 36.54 6.09*
DCES-P week 0 35.93 8.23 34.37 8.68
DCES-P week 4 39.33 8.58 37.50 7.37
DCES-P week 8 39.87 10.62 41.36 7.93
DCES-P week 16 42.38 10.51 46.21 6.64
Note: DCES-O, optimistic outcome expectancy subscale of DCES; DCES-P, pes-
simistic outcome expectancy subscale of DCES. DCES-P items were reverse
scored. *Significant group difference, p < .05.
Table 2
Fit indices for latent growth curve and cross-lagged panel models.
Latent growth curve models (LGCMs)
Treatment Expectancy χ2 (df), p value CFI RMSEA SRMR
Medication DCES-P – – – –
DCES-O 1.63 (3), p= .65 1.00 <0.01 0.08
CBT DCES-P 3.97 (5), p = .55 1.00 <0.01 0.11
DCES-O 4.82 (7), p = .68 1.00 <0.01 0.16
Multi-Group Cross-Lagged Panel Models (CLPMs)
Model Expectancy Outcome χ2 (df), p value CFI RMSEA SRMR
1. DCES-P BDI-II 2.46 (8), p = .96 1.00 <0.01 0.03
1.* 2.35 (4), p = .67 1.00 <0.01 0.03
2. HAMD 7.46 (8), p = .49 1.00 <0.01 0.03
2.* 6.18 (4), p = .19 0.99 0.10 0.04
3. DCES-O BDI-II 14.84 (8), p = .06 0.96 0.13 0.06
3.* 2.36 (4), p = .67 1.00 <0.01 0.03
4. HAMD 10.18 (8), p = .25 0.98 0.07 0.07
4.* 3.00 (4), p = .56 1.00 <0.01 0.03
Note: In the LGCMs, the model for DCES-P for the medication group is not
presented due to notable misspecification; it was not interpreted.
*Final CLPMs, which include paths from week 0 to week 16.
2 The addition of this path improved model fit for all models, with the ex-
ception of Model 2. To maintain consistency across models, the additional paths
from week 0 to 16 were included in all four models.
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Table 3
Parameter estimates for final latent growth curve models.
Model Parameters Medication CBT
DCES-P Mean (SE) Variance (SE) Mean (SE) Variance (SE)
Intercept _ _ 34.54 (1.10)** 48.47(13.66)**
Slope _ _ 2.75 (0.26)** 2.22 (1.27)
Growth factor
Correlation
(r, 95% CI)
_ −0.48 [−0.75, −0.20]*
DCES-O Intercept 29.06 (0.81)** 20.96 (9.63)* 30.78 (0.59)** 9.13 (2.63)**
Slope 1.05 (0.27)** 1.19 (0.62) 1.47 (0.21)** _
Growth factor
Correlation
(r, 95% CI)
−0.10 [−0.79, 0.59] _
Note: *p < .05, **p < .001. Unstandardized mean and variance estimates are reported. Standardized covariance (correlations) between growth factors are reported.
The model for DCES-P growth in the medication group is not presented due to notable misspecification.
Fig. 1. Model 1 Cross-lagged panel model of DCES-P and BDI-II. Only significant paths are shown. e1-e4= error residual terms. *= p < .05, **= p < .001. Results
of the Wald test did not support differences between treatment groups in the path from week 8 DCES-P and week 16 BDI-II (χ2= 0.04(1, n=104), p = .852).
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Using the HAMD (Model 4), a significant difference between med-
ication and CBT (χ2(1, n=104)= 5.61, p = .02) was found in the path
from mid-treatment DCES-O score to end of treatment HAMD score.
That is, higher DCES-O at mid-treatment predicted lower end of treat-
ment HAMD in the medication group (β=−0.45, p < .001), not the
CBT group (β=0.030, p = .82). Similar to Model 3, higher DCES-O at
pre-treatment predicted lower HAMD scores at the end of treatment in
the CBT arm only, although the Wald-test did not reach significance in
Model 4 (χ2(1, n=104)=1.46, p = .23). Additionally, no group dif-
ferences were seen in the paths between week 0 DCES-O and week 8
HAMD. Finally, similar to Model 3, there were no significant paths from
depression to outcome expectancy in the medication group; however,
HAMD at week 0 was negatively predictive of DCES-O at the end of
treatment in the CBT group (β=−0.28, p = .05).
Taken together, similar patterns of the relation between optimistic
outcome expectancy and depression were seen in the BDI-II (Model 3)
and HAMD (Model 4) models. That is, for the medication group, higher
DCES-O at mid-treatment predicted lower depression at the end of
treatment. In the HAMD model, the results of the Wald test supported
that this path was specific to treatment with medication over treatment
with CBT. Moreover, both models demonstrated that higher pre-treat-
ment optimistic expectancy predicted lower depression at the end of
treatment. The results of the Wald test in the BDI-II model suggested
that this effect of pre-treatment expectancy on post-treatment depres-
sion was specific to CBT over medication.3
Fig. 2. Model 3 Cross-lagged panel model of DCES-O and BDI-II. Only significant paths are shown. e1-e4= error residual terms. *= p < .05, **= p < .001. Results
of the Wald test did support differences between treatment groups in the path from week 0 DCES-O and week 16 BDI-II (χ2= 6.07 (1, n=104), p= .014).
3 As age and sex demonstrated significant associations with depression and
expectancy scores, these variables were included as independent covariates in
the cross-lagged models. Incorporation of age as a covariate did not change
study results. Incorporation of sex as a covariate in these models resulted in
inadmissible solutions.
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4. Discussion
The present study explored differences in the trajectory of outcome
expectancy in pharmacotherapy versus CBT for depression. This ran-
domized design enabled the evaluation of the role of outcome ex-
pectancy as a putative mechanism for depression reduction as these
treatments progressed. The recently developed DCES permitted the
examination of both optimistic expectancy and pessimistic expectancy
in this context.
4.1. Change in expectancy over time
Results from latent growth model analyses supported significant
positive, linear improvement in optimistic and pessimistic expectancy
in CBT, reflecting consistent change throughout psychotherapy. In
contrast, a clear significant quadratic trend in optimistic outcome ex-
pectancy was seen in pharmacotherapy, reflecting significant steep
growth from week 0 to week 8, followed by a slight decrease by the end
of the treatment. Increases in expectancy throughout the course of CBT
has been established in previous investigations in patients with gen-
eralized anxiety disorder (Newman and Fisher, 2010), mixed anxiety
disorders (Brown et al., 2014), seasonal affective disorder (Meyerhoff
and Rohan, 2016), and most recently in MDD (Vîslă et al., 2018). To the
best of our knowledge, this is the first investigation to examine the
trend of patient expectancy during antidepressant treatment. Previous
investigations of this cognitive construct in pharmacotherapeutic stu-
dies have largely been limited to exploring the influence of pre-treat-
ment expectancy on end of treatment outcome (Krell et al., 2004; Meyer
et al., 2002; Rutherford and Roose, 2013; Sotsky et al., 1991). Evidence
for dynamic changes in expectancy as treatment progresses signals a
potential mechanistic role of this construct to therapeutic improvement
with pharmacotherapy.
Differing trajectories of growth across the two treatment modalities
precluded direct comparisons of the growth parameters (slope and in-
tercept) between groups, and may reflect either treatment-specific
processes influencing change in this construct, or similar processes
acting at different time points throughout the course of the two treat-
ments. Although the extant literature on how expectancy changes over
treatment for MDD is notably small, evidence is sufficient to suggest
processes that are largely common across treatments.
In a recent study in which patients with MDD were randomized into
either an open-label citalopram group (100% chance of active drug) or
a placebo-controlled citalopram group (50% chance of active drug),
revealing group assignment post-randomization enhanced patient out-
come expectancy only in the open-label group (Rutherford et al., 2017).
Both groups were informed of the effectiveness of citalopram for de-
pression and only differed in the level of certainty in receiving this
medication, providing some support for the importance of treatment
rationale for early expectancy change in pharmacotherapy treatment.
Moreover, there is growing evidence for the influence of therapeutic
alliance on treatment outcomes in the placebo arm (i.e., robustness of
placebo effect) (Rutherford and Roose, 2013; Zilcha-Mano et al., 2015).
Insofar as patient expectations of improvement underscore placebo ef-
fects (Rutherford and Roose, 2013), building alliance may represent an
important process to expectancy change in treatment with medication.
Relatedly, research investigating the influence of treatment ratio-
nale on patient expectations in CBT suggest that providing a rationale
alone significantly increases expectancy in socially anxious analogue
samples (Ahmed and Westra, 2009; Ametrano et al., 2017). As sug-
gested by Newman and Fisher (2010), although the fulsome rationale is
typically presented at the beginning of treatment, there are opportu-
nities throughout CBT to reiterate elements of the rationale, particu-
larly as new strategies are being introduced (Newman and Fisher, 2010)
or homework is reviewed, facilitating consistent growth in expectancy.
Second, CBT strategies during the latter half of treatment (i.e. cognitive
restructuring and behavioral experiments) may directly influence this
construct (Newman and Fisher, 2010). Finally, as in pharmacotherapy,
there is some support for the effect of strong alliance on outcome ex-
pectations in CBT (Westra et al., 2011; Visla et al., 2016).
4.2. Outcome expectancy as a putative mechanism
Our hypothesis that outcome expectancy during treatment would
demonstrate predictive associations with depression improvement in
CBT, but not pharmacotherapy, was not supported by the results of the
cross-lagged panel analyses. For the CBT group, greater pre-treatment
optimistic expectancy (week 0) predicted lower post-treatment de-
pression (week 16). In the pharmacotherapy group, higher optimistic
expectancy at mid-treatment (week 8) was predictive of lower post-
treatment depression. The relation between pessimistic expectancy and
depression did not differ across treatment groups. Indeed, in both CBT
and pharmacotherapy, lower pessimistic expectancy (seen as higher
scores on the pessimistic subscale of the DCES) at mid-treatment pre-
dicted lower depression at the end of treatment.
Our results are consistent with previous work establishing a small
effect between pre-treatment optimistic outcome expectancy and post-
treatment symptom severity in psychotherapy (Constantino et al.,
2011). This finding supports long-standing suggestions that the begin-
ning of therapy with CBT is a crucial point in which to shape treatment
outcome by strengthening optimistic expectancies for improvement
(Constantino et al., 2012; Ilardi and Craighead, 1994). Previous work
on the possible mechanistic processes linking pre-treatment expectancy
and post-treatment outcome implicate alliance formation (Tsai et al.,
2014; Visla et al., 2016; Webb et al., 2014), early homework com-
pliance (Westra et al., 2007) and the use of CBT skills (Webb et al.,
2013). Importantly, results from Visla et al. (2016) support the presence
of chain associations throughout treatment by which baseline ex-
pectancy leads to early alliance formation which, in turn, influences
early-treatment expectancy, leading to more favourable post-treatment
outcomes. In some support of this idea, pre-treatment outcome ex-
pectancy (both optimistic and pessimistic) was significantly related to
the number of sessions completed by participants in the CBT group (rs
of 0.42 and 0.42, ps = 0.001). In contrast, pre-treatment expectancy
was not related to the total number of weeks of medication received, or
the total number of visits with the psychiatrist, in the pharmacotherapy
group.
Our lack of association between during-treatment optimistic ex-
pectancy and depression outcomes in CBT is inconsistent with the re-
sults of a previous study, wherein a significant effect of higher week 3
expectancy on lower end of treatment depression was evidenced
(Meyerhoff and Rohan, 2016). However, the aforementioned study
differs from the present investigation in several respects, including their
sample (seasonal depression only), treatment duration (six weeks in
duration), and measurement of expectancy (which combined ex-
pectancy and credibility). These results may suggest that optimistic
expectations during treatment are impactful only very early on where
the processes of alliance formation and homework compliance gain the
most traction. In line with these results, Visla et al. (2016) saw a robust
negative association between week 3 expectancy and post-treatment
depression at week 10.
Unlike optimistic expectancy, a negative association was seen in
week 8 expectancy and post-treatment depression in CBT for pessimistic
expectancy. Poor treatment outcome was seen in individuals who
maintained higher pessimistic expectancies at the midpoint of treat-
ment. This differential effect of optimistic versus pessimistic ex-
pectancies aligns with extant theories of goal attainment which postu-
late persistent effort stemming from positive expectancies, and
disengagement/abandonment stemming from negative expectancies
(Carver and Scheier, 2000; Meyer et al., 2002). Although optimistic and
pessimistic outcome expectancy subscales were highly correlated in our
study (rs = 0.68 to 0.76, ps < 0.001, across time points), the differ-
ential effects suggests that each subscale represents a unique
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component of this construct, in line with the results of the original
validation for this scale (Eddington et al., 2014). Future studies are
needed to replicate the proposed differential roles of positive (opti-
mistic) versus negative (pessimistic) expectancies in CBT, particularly
as they relate to the previously indicated mediators of alliance, en-
gagement, compliance and development of CBT skills.
As noted by Rutherford and Roose (2013), expectancy has largely
been conceived as an unwanted factor to be controlled for in anti-
depressant research. Our results of robust negative associations be-
tween expectancy (both optimistic and pessimistic) at week 8 and post-
treatment depression support a possible mechanistic role of this factor
in pharmacotherapy treatment. Notably, previous studies on this topic
are scant, but existing work points to similar mechanisms as those
evidenced in CBT, specifically therapeutic alliance (Meyer et al., 2002).
As suggested by Rutherford et al. (2017), future work is needed to
better explicate the influence of expectancy in pharmacotherapy, po-
tentially to inform revisions to existing clinical management protocols
to incorporate optimization of expectancy effects (Rutherford et al.,
2017).
4.3. Limitations
The results of this investigation meaningfully extend the literature
on outcome expectancy; however, this study is not without limitations.
First, our smaller sample size limited the complexity of cross-lagged
models we were able to estimate. The nature of the data (i.e., different
trajectories across treatments) dictated the use of group-specific ana-
lyses, which further limited our statistical power. Moreover, the pessi-
mistic expectancy growth model in the pharmacotherapy group was
uninterpretable, as was the optimistic expectancy model including the
random slope variable. Inadmissible solutions may suggest mis-
specification due to failure to include relevant predictors in our models
(Kline, 2011). Moreover, previous simulation studies have shown that a
number of factors, including small sample size and fewer assessments,
may increase the likelihood of inadmissible solutions when estimating
growth (Diallo et al., 2014). Taken together, while the current results
provide an important initial exploration of differential changes in out-
come expectancy across different treatment modalities, future studies
with more frequent assessments of outcome expectancy and larger
sample sizes allowing for more complex modeling are needed. Second,
our investigation of the role of outcome expectancy as a putative me-
chanism was circumscribed to exploring the cross-lagged associations in
point-estimates of expectancy and depression during treatment, and we
did not explore the specific role of changes in this construct. Future
studies with larger sample sizes will be necessary to substantiate out-
come expectancy as a mechanism by measuring the effect of change
throughout treatment, particularly by capturing more frequent assess-
ments early on. Moreover, as the parent randomized trial largely fo-
cused on the mediational role of cognition in therapeutic response,
variables of alliance, treatment adherence (i.e., homework compliance
and CBT skill acquisition for CBT, and pill counts and blood levels for
pharmacotherapy) – possible mediators of the expectancy-outcome link
– were not able to be included. As such, we were unable to explore the
putative associations of these proposed processes. Nevertheless, our use
of a randomized design in this study enabled exploration of treatment-
specific roles of outcome expectancy in the two most widely used
treatments for MDD.
5. Conclusions
To the best of our knowledge, this is the first study to explore
changes in outcome expectancy throughout the course of anti-
depressant treatment, as well as to compare the relation between ex-
pectancy and outcome across CBT and pharmacotherapy. The results of
this study reiterate the critical role of pre-treatment expectancy for CBT
response, and support a possible mechanistic role in antidepressant
response. Indeed, the status of outcome expectation as a common factor
in psychotherapy may be extended to represent a possible common
mechanism in the treatment of depression overall. However, larger
studies with more frequent assessments of during treatment expectancy
will be needed to validate these results. Clinically, these results im-
plicate outcome expectancy as a potentially important target for both
psychological and pharmacological treatments for MDD. More specifi-
cally, as patients presenting with higher optimistic beliefs before
treatment begins benefit from CBT, efforts to bolster optimism will be
crucial early in treatment. Initial sessions (e.g., educating the patient to
the model, goal setting) might include traditional psychoeducation re-
garding research evidence for the benefits of CBT as well as a strength-
based approach with a focus on patient resilience, to target optimistic
outcome expectancies even further. For pharmacotherapy, clinical
management protocols may benefit from strategies to enhance opti-
mism applied throughout the course of treatment. Psychoeducation
regarding the time course of medication effects and the opportunities to
switch or augment pharmacotherapy as needed to maximize ther-
apeutic benefit, and working with patients to increase compliance,
motivation, and ultimately, their own sense of responsibility and em-
powerment in their recovery, may be useful. Moreover, an important
future direction includes greater attention to expectancy type (opti-
mistic versus pessimistic) in studies aiming to further explicate this
construct.
Conflicts of interest
All authors report no conflicts of interest.
Contributors
LCQ was the primary investigator of the original trial and oversaw
study design. Authors DJAD, RMB, DSSL, and LNR assisted in the study
design and data collection in the original trial. TT and LCQ were in-
volved in generating the research questions in the current study, as well
as conducting analyses, interpreting results and drafting the initial
manuscript. All authors contributed to and approved the final manu-
script.
Role of funding source
This research was supported by the Ontario Mental Health
Foundation (OMHF). This source was not involved in study conduct,
study analyses nor reporting of results.
Acknowledgments
We wish to extend our gratitude to study participants and research
staff in the original trial for their time and effort.
References
Ahmed, M., Westra, H.A., 2009. Impact of a treatment rationale on expectancy and en-
gagement in cognitive behavioral therapy for social anxiety. Cognit. Ther. Res. 33,
314–322.
Ametrano, R.M., Constantino, M.J., Nalven, T., 2017. The influence of expectancy per-
suasion techniques on socially anxious analogue patients’ treatment beliefs and
therapeutic actions. Int. J. Cognit. Ther. 10, 187–205.
Beck, A.T., Rush, A.J., Shaw, B.F., Emery, G., 1979. Cognitive Therapy of Depression.
Beck, A.T., Steer, R.A., Brown, G.K., 1996. Manual for the Beck Depression Inventory–II
(BDI-II). Psychological Corporation, San Antonio.
Brown, L.A., Wiley, J.F., Wolitzky-Taylor, K., Roy-Byrne, P., Sherbourne, C., Stein, M.B.,
Sullivan, G., Rose, R.D., Bystritsky, A., Craske, M.G., 2014. Changes in self-efficacy
and outcome expectancy as predictors of anxiety outcomes from the CALM study.
Depress. Anxiety 31, 678–689.
Carver, C.S., Scheier, M.F., 2000. Chapter 3 - on the structure of behavioral self-regula-
tion. Handb. Self-Regulation. pp. 41–84.
Constantino, M.J., Ametrano, R.M., Greenberg, R.P., 2012. Clinician interventions and
participant characteristics that foster adaptive patient expectations for psychotherapy
and psychotherapeutic change. Psychotherapy 49, 557–569.
T. Thiruchselvam, et al. Journal of Affective Disorders 251 (2019) 121–129
128
Constantino, M.J., Arnkoff, D.B., Glass, C.R., Ametrano, R.M., Smith, J.A.Z., 2011.
Expectations. J. Clin. Psychol. 67, 184–192.
Cuijpers, P., Berking, M., Andersson, G., Quigley, L., Kleiboer, A., Dobson, K.S., 2013. A
meta-analysis of cognitive-behavioural therapy for adult depression, alone and in
comparison with other treatments. Can. J. Psychiatr. 58, 376–385.
Curran, P.J., Obeidat, K., Losardo, D., 2010. Twelve frequently asked questions about
growth curve modeling. J. Cognit. Dev. 11, 121–136.
DeRubeis, R.J., Evans, M.D., Hollon, S.D., Garvey, M.J., Grove, W.M., Tuason, V.B., 1990.
How does cognitive therapy work? Cognitive change and symptom change in cog-
nitive therapy and pharmacotherapy for depression. J. Consult. Clin. Psychol. 58,
862–869.
Diallo, T.M.O., Morin, A.J.S., Parker, P.D., 2014. Statistical power of latent growth curve
models to detect quadratic growth. Behav. Res. Methods 46, 357–371.
Dozois, D.J.A., Westra, H.A., 2005. Development of the Anxiety change expectancy scale
(ACES) and validation in college, community, and clinical samples. Behav. Res. Ther.
43, 1655–1672.
Eddington, K.M., Dozois, D.J., Backs-Dermott, B.J., 2014. Evaluation of the internal
consistency, factor structure, and validity of the depression change expectancy scale.
Assessment 21, 607–617.
Evans, M., Rohan, K.J., Sitnikov, L., Mahon, J.N., Nillni, Y.I., Lindsey, K.T., Vacek, P.M.,
2013. Cognitive change across cognitive-behavioral and light therapy treatments for
seasonal affective disorder: what accounts for clinical status the next winter? Cognit.
Ther. Res. 37, 1201–1213.
Ferrari, A.J., Charlson, F.J., Norman, R.E., Flaxman, A.D., Patten, S.B., Vos, T., Whiteford,
H.A., 2013. The epidemiological modelling of major depressive disorder: application
for the Global Burden of Disease Study 2010. PLoS One 8, e69637.
First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1995. Structured Clinical
Interview For DSM-IV Axis I Disorders–Patient Edition (SCID-I/P; Version 2.0).
Biometrics Research Department, New York.
Frank, J.D., 1961. Persuasion and Healing: A Comparative Study of Psychotherapy. Johns
Hopkins University Press, Oxford, England.
Garratt, G., Ingram, R.E., Rand, K.L., Sawalani, G., 2007. Cognitive processes in cognitive
therapy: evaluation of the mechanisms of change in the treatment of depression. Clin.
Psychol. Pract. 14, 224–239.
Glass, C.R., Arnkoff, D.B., Shapiro, S.J., 2001. Expectations and preferences. Psychother.
Theory, Res. Pract. Train. 38, 455–461.
Greenberg, R.P., Constantino, M.J., Bruce, N., 2006. Are patient expectations still relevant
for psychotherapy process and outcome? Clin. Psychol. Rev. 26, 657–678.
Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23,
56–62.
Hofmann, S.G., Asnaani, A., Vonk, I.J.J., Sawyer, A.T., Fang, A., 2012. The efficacy of
cognitive behavioral therapy: a review of meta-analyses. Cognit. Ther. Res. 36,
427–440.
Hu, L.T., Bentler, P.M., 1999. Cutoff criteria for fit indexes in covariance structure ana-
lysis: conventional criteria versus new alternatives. Struct. Equations Model. 6, 1–55.
Ilardi, S.S., Craighead, W.E., 1994. The role of nonspecific factors in cognitive‐behavior
therapy for depression. Clin. Psychol. Sci. Pract. 1, 138–155.
Kim, E.S., Willson, V.L., 2014. Testing measurement invariance across groups in long-
itudinal data: multigroup second-order latent growth model. Struct. Equation Model.
21, 566–576.
Kline, R.B., 2011. Principles and Practice of Structural Equation Modeling, third ed. .
Krell, H.V, Leuchter, A.F., Morgan, M., Cook, I.A., Abrams, M., 2004. Subject expectations
of treatment effectiveness and outcome of treatment with an experimental anti-
depressant. J. Clin. Psychiatr. 65, 1174–1179.
Kuiper, R.M., Ryan, O., 2018. Drawing conclusions from cross-lagged relationships: re-
considering the role of the time-interval. Struct. Equation Model. 25, 809–823.
Lam, R.W., Kennedy, S.H., Grigoriadis, S., McIntyre, R.S., Milev, R., Ramasubbu, R.,
Parikh, S.V., Patten, S.B., Ravindran, A.V., 2009. Canadian Network for Mood and
Anxiety Treatments (CANMAT) clinical guidelines for the management of major
depressive disorder in adults. III. Pharmacotherapy. J. Affect. Disord. 117 (Suppl. 1),
S26–S43.
Lorenzo-Luaces, L., German, R.E., DeRubeis, R.J., 2015. It's complicated: the relation
between cognitive change procedures, cognitive change, and symptom change in
cognitive therapy for depression. Clin. Psychol. Rev. 41, 3–15.
MacLeod, A.K., 1996. Affect, emotional disorder, and future-directed thinking. Cognit.
Emotion 10, 69–86.
Meyer, B., Pilkonis, P.A., Krupnick, J.L., Egan, M.K., Simmens, S.J., Sotsky, S.M., 2002.
Treatment expectancies, patient alliance, and outcome: further analyses from the
National Institute of Mental Health Treatment of Depression Collaborative Research
Program. J. Consult. Clin. Psychol. 70, 1051–1055.
Meyerhoff, J., Rohan, K.J., 2016. Treatment expectations for cognitive-behavioral
therapy and light therapy for seasonal affective disorder: change across treatment and
relation to outcome. J. Consult. Clin. Psychol., J. Consult. Psychol. 84, 898–906.
Miranda, R., Fontes, M., Marroquín, B., 2008. Cognitive content-specificity in future ex-
pectancies: role of hopelessness and intolerance of uncertainty in depression and GAD
symptoms. Behav. Res. Ther. 46, 1151–1159.
Muthén, L., Muthén, B., 2017. Mplus User's Guide, eighth ed. Muthén & Muthén, Los
Angeles.
Newman, M.G., Fisher, A.J., 2010. Expectancy/credibility change as a mediator of cog-
nitive behavioral therapy for generalized anxiety disorder: mechanism of action or
proxy for symptom change? Int. J. Cognit. Ther. 3, 245–261.
Newsom, J.T., 2015. Longitudinal Structural Equation Modeling: A Comprehensive
Introduction. Routledge, New York.
Parikh, S.V., Quilty, L.C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis,
V., Kennedy, S.H., Lam, R.W., MacQueen, G.M., Milev, R.V, Ravindran, A.V., Uher,
R., CANMAT Depression Work Group, 2016. Canadian Network for Mood and
Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of
adults with major depressive disorder: section 2. Psychological treatments. Can. J.
Psychiatr. 61, 524–539.
Preacher, K.J., Wichman, A.L., MacCallum, R.C., Briggs, N.E., 2008. Quantitative
Applications in the Social Sciences: Latent growth curve modeling. Sage Publications,
Thousand Oaks, CA.
Quilty, L.C., Dozois, D.J.A., Lobo, D.S.S., Ravindran, L.N., Bagby, R.M., 2014. Cognitive
structure and processing during cognitive behavioral therapy vs. pharmacotherapy
for depression. Int. J. Cognit. Ther. 7, 235–250.
Rot, M.A.H., Mathew, S.J., Charney, D.S., 2009. Neurobiological mechanisms in major
depressive disorder. Can. Med. Assoc. J. 180, 305–313.
Rutherford, B.R., Roose, S.P., 2013. A model of placebo response in antidepressant
clinical trials. Am. J. Psychiatr. 170, 723–733.
Rutherford, B.R., Wager, T.D., Roose, S.P., 2010. Expectancy and the treatment of de-
pression: a review of experimental methodology and effects on patient outcome. Curr.
Psychiatr. Rev. 6, 1–10.
Rutherford, B.R., Wall, M.M., Brown, P.J., Choo, T.-H., Wager, T.D., Peterson, B.S.,
Chung, S., Kirsch, I., Roose, S.P., 2017. Patient expectancy as a mediator of placebo
effects in antidepressant clinical trials. Am. J. Psychiatr. 174, 135–142.
Schulte, D., 2008. Patients’ outcome expectancies and their impression of suitability as
predictors of treatment outcome. Psychother. Res. 18, 481–494.
Snyder, C.R., Ilardi, S.S., Cheavens, J., Michael, S.T., Yamhure, L., Sympson, S., 2000. The
role of hope in cognitive-behavior therapies. Cognit. Ther. Res. 24, 747–762.
Sotsky, S.M., Glass, D.R., Trade Shea, M., Pilkonis, P.A., Collins, J.F., Elkin, I., Watkins,
J.T., Imber, S.D., Leber, W.R., Moyer, J., Oliveri, M.E., 1991. Patient predictors of
response to psychotherapy and pharmacotherapy: findings in the NIMH treatment of
depression collaborative research program. Am. J. Psychiatr. 148, 997–1008.
Stewart-Williams, S., Podd, J., 2004. The placebo effect: dissolving the expectancy versus
conditioning debate. Psychol. Bull. 130, 324–340.
Swift, J.K., Derthick, A.O., 2013. Increasing hope by addressing clients’ outcome ex-
pectations. Psychotherapy (Chic). 50, 284–287.
Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L.,
Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs,
M.M., Balasubramani, G.K., Fava, M., 2006. Evaluation of outcomes with citalopram
for depression using measurement-based care in STAR*D: implications for clinical
practice. Am. J. Psychiatr. 163, 28–40.
Tsai, M., Ogrodniczuk, J.S., Sochting, I., Mirmiran, J., 2014. Forecasting success: patients’
expectations for improvement and their relations to baseline, process and outcome
variables in group cognitive-behavioural therapy for depression. Clin. Psychol.
Psychother. 21, 97–107.
Visla, A., Constantino, M.J., Newkirk, K., Ogrodniczuk, J.S., Sochting, I., 2016. The re-
lation between outcome expectation, therapeutic alliance, and outcome among de-
pressed patients in group cognitive-behavioral therapy. Psychother. Res. 28,
446–456.
Vîslă, A., Flückiger, C., Constantino, M.J., Krieger, T., Grosse Holtforth, M., 2018. Patient
characteristics and the therapist as predictors of depressed patients’ outcome ex-
pectation over time: a multilevel analysis. Psychother. Res. 1–14. https://doi.org/10.
1080/10503307.2018.1428379.
Vorstenbosch, V., Laposa, J.M., 2015. Treatment expectancy for anxiety change and re-
sponse to cognitive behavioral therapy for OCD. J. Obsessive Compulsive Relat.
Disord. 5, 55–60.
Wampold, B.E., Minami, T., Tierney, S.C., Baskin, T.W., Bhati, K.S., 2005. The placebo is
powerful: estimating placebo effects in medicine and psychotherapy from rando-
mized clinical trials. J. Clin. Psychol. 61, 835–854.
Webb, C.A., Beard, C., Auerbach, R.P., Menninger, E., Bjorgvinsson, T., 2014. The ther-
apeutic alliance in a naturalistic psychiatric setting: temporal relations with depres-
sive symptom change. Behav. Res. Ther. 61, 70–77.
Webb, C.A., Kertz, S.J., Bigda-Peyton, J.S., Bjorgvinsson, T., 2013. The role of pretreat-
ment outcome expectancies and cognitive-behavioral skills in symptom improvement
in an acute psychiatric setting. J. Affect. Disord. 149, 375–382.
Westra, H.A., Constantino, M.J., Aviram, A., 2011. The impact of alliance ruptures on
client outcome expectations in cognitive behavioral therapy. Psychother. Res. 21,
472–481.
Westra, H.A., Dozois, D.J.A., Marcus, M., 2007. Expectancy, homework compliance, and
initial change in cognitive-behavioral therapy for anxiety. J. Consult. Clin. Psychol.
75, 363–373.
Zilcha-Mano, S., Roose, S.P., Barber, J.P., Rutherford, B.R., 2015. Therapeutic alliance in
antidepressant treatment: cause or effect of symptomatic levels? Psychother.
Psychosom. 84, 177–182.
T. Thiruchselvam, et al. Journal of Affective Disorders 251 (2019) 121–129
129
